Table 1. Strategies for targeting lncRNA in cancer therapy.

Strategies	Effects	Advantage	Limitation
siRNA, ASO, miRNA	RNA degradation	Specific, potent effect	Stability, delivery
Cas9	Gene knockout, DNA editing, gene mutation, etc.	Versatile and long-term effect	Genomic context dependent, PAM requirement, targeting efficiency, in vivo delivery
PspCas13b	RNA cleavage	Programmable targeting, less sequence constraint	Targeting efficiency, in vivo delivery
REPAIR (dCas13-ADAR)	RNA editing	Programmable editing	Targeting efficiency, in vivo delivery
Small molecules	RNA binding	Convenient in vivo delivery	Non-specificity, non-programmable targeting

siRNA: small interfering RNA; ASO: antisense oligonucleotide; miRNA: microRNA; Cas9: CRISPR-associated 9; PspCas13b: CRISPR-associated 13 from Prevotella sp. P5-125; REPAIR: RNA Editing for Programmable A to I Replacement; dCas13: catalytically inactive PspCas13b; ADAR: adenosine deaminase acting on RNA